GBM44 GBM Model

GBM44, a Patient-Derived Xenograft (PDX) model, provides a window into the world of brain cancer. Explore its characteristics to uncover new treatment strategies and mechanisms. PDX models like GBM44 are indispensable for preclinical drug discovery because they replicate the patient’s tumor heterogeneity. Researchers can use GBM44 to screen and prioritize drug candidates, increasing the likelihood of successful clinical translation. By leveraging GBM44, you contribute to the development of targeted therapies and better outcomes for brain cancer patients.

Model Details

Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM44
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Temozolomide)
WES: Yes
RNAseq: Yes
Methylation: Yes
PDX Treatment: Yes
Patient Treatment History: Yes

GBM44 Survival

Survival of orthotopic intracranial implanted  GBM44 in Nu/Nu mice  (n=5)

Request Additional GBM Model Data

Contact Us

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.

Skip to content